Pre-print: Waning of BNT162b2 or ChadOx1 mRNA Boosters against symptomatic infection and severe COVID-19 in Brazil and Scotland
April 2022: Pre-print article published on preprints with The Lancet investigates the waning effectiveness of booster vaccines from Pfizer BioNTech (BNT162b2) and Oxfrord-AstraZeneca (ChadOx1), against symptomatic infection and severe COVID-19 in Brazil and Scotland.
Waning of mRNA Boosters after Homologous Primary Series with BNT162b2 or ChadOx1 Against Symptomatic Infection and Severe COVID-19 in Brazil and Scotland: A Test-Negative Design Case-Control Study
Cerqueira-Silva, T.; Shah, S.A.; Robertson, C.; Sanchez, M. N.; et. al.
Pre-prints with the Lancet
Published online on: 14 April 2022
Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4082927
Note
This is article has since been peer reviewed.
Read the summary of the peer reviewed article